<DOC>
	<DOCNO>NCT02159690</DOCNO>
	<brief_summary>This study investigate pathologic effect combination enzalutamide , abiraterone acetate , dutasteride , degarelix give 12 week prior prostatectomy men localize prostate cancer . Enzalutamide , androgen receptor ( AR ) antagonist , block bind testosterone AR well prevent nuclear translocation AR DNA binding . Abiraterone acetate inhibits CYP17 pathway , involve formation androgen . Dutasteride 5-alpha-reductase inhibitor block conversion testosterone dihydrotestosterone . Degarelix , gonadotropin-releasing hormone ( GnRH ) antagonist , bind GnRH receptor pituitary gland thus suppress testosterone release testis . Therefore hypothesized combination enzalutamide , abiraterone acetate , dutasteride , degarelix result near-complete AR inhibition produce favorable pathologic change 12 week therapy .</brief_summary>
	<brief_title>A Phase II Neoadjuvant Study Enzalutamide , Abiraterone Acetate , Dutasteride Degarelix Men With Localized Prostate Cancer Pre-prostatectomy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>1 . Willing able provide write informed consent . 2 . Age ≥ 18 year 3 . Eastern cooperative group ( ECOG ) performance status ≤2 4 . Documented histologically confirm adenocarcinoma prostate 5 . Willing undergo prostatectomy primary treatment localized prostate cancer 6 . High risk prostate cancer ( per NCCN criterion ) : Gleason score 810 T3a PSA &gt; 20 ng/mL Or Veryhigh risk prostate cancer ( per NCCN criterion ) : T3b T4 7 . Serum testosterone ≥150 ng/dL 8 . Able swallow study drug whole tablet 9 . Willing take abiraterone acetate empty stomach ( food consume least two hour one hour dosing ) . 10 . Willing use condom sex pregnant woman , use condom another effective method birth control sex woman childbearing potential . These measure require one week treatment abiraterone . 1 . Prior local therapy treat prostate cancer ( e.g . radical prostatectomy , radiation therapy , brachytherapy ) 2 . Prior use enzalutamide abiraterone acetate 3 . Prior ongoing systemic therapy prostate cancer include , limited : 1 . Hormonal therapy ( e.g . leuprolide , goserelin , triptorelin , degarelix ) 2 . CYP17 inhibitor ( e.g . ketoconazole ) 3 . Antiandrogens ( e.g . bicalutamide , nilutamide ) 4 . Second generation antiandrogens ( e.g . enzalutamide , ARN509 ) 5 . Immunotherapy ( e.g . sipuleucelT , ipilimumab ) 6 . Chemotherapy ( e.g . docetaxel , cabazitaxel ) 4 . Evidence serious and/or unstable preexist medical , psychiatric condition ( include laboratory abnormality ) could interfere patient safety provision inform consent participate study . 5 . Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule . 6 . Abnormal bone marrow function [ absolute neutrophil count ( ANC ) &lt; 1500/mm3 , platelet count &lt; 100,000/mm3 , hemoglobin &lt; 9 g/dL ] 7 . Abnormal liver function ( bilirubin , AST , ALT ≥ 3 x upper limit normal ) 8 . Abnormal kidney function ( serum creatinine ≥ 2 x upper limit normal ) 9 . Abnormal cardiac function manifest NYHA ( New York Heart Association ) class III IV heart failure history prior myocardial infarction ( MI ) within last five year prior enrollment study . 10 . History prior cardiac arrhythmia .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostatectomy</keyword>
	<keyword>localized prostate cancer</keyword>
</DOC>